ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Steve Cutler: ‘People understand what a clinical trial is now’
An interview with CEO Steve Cutler on ICON's recent acquisition of PRA Health Sciences.
Inside the Pfizer/BioNTech COVID-19 vaccine trial: ‘We knew the world was watching and waiting for results’
An article featuring commentary from Dr. Nuala Murphy on ICON’s learnings from conducting the Pfizer/BioNTech trial.
Mind the gap: Managed access programmes as an alternative to long-term follow up studies
Veronica Gutierrez Martinez and Michael Tokar discuss the challenges of setting up MAPs and the various considerations that must be tackled for a successful programme.
Ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic
Jack Martin and Deirdre Albertson provide insights on ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic.
Minimising the risk of mistakes in HTA
An article in Pharmexec examining mistakes made in relation to Health Technology Assessments (HTA) and strategies to help reduce risks of future mistakes.
How COVID-19 has changed pharmacovigilance
How COVID-19 has changed pharmacovigilance. Explores how drug safety can be ensured while numerous vaccines and treatments come to market to deal with COVID-19.
How scientists John Climax and Dr Ronan Lambe created an icon
An article reporting on the growth of ICON as it acquires PRA Health Sciences.
ICON to acquire PRA Health Sciences in $12bn deal
ICON is set to acquire rival contract research organisation (CRO) PRA Health Sciences in a deal worth approximately $12bn.
ICON CEO on PRA deal: Groundwork laid for faster trials (Radio)
A radio intervew with ICON CEO Steve Cutler about the ICON-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.
ICON to acquire PRA for $12B as COVID-19 spurs CRO consolidation
ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, in a deal that continues the consolidation of contract research organisations into a handful of corporate giants.